Extract

The primary objective of this study is to demonstrate the superiority of MCI-196 over placebo and non-inferiority with simvastatin in reducing serum low-density lipoprotein (LDL)-cholesterol in subjects with chronic kidney disease Stage V on dialysis. This study incorporates a Washout Period and two treatment periods - an active comparison phase and a placebo-controlled withdrawal phase.

Inclusion criteria

• chronic kidney disease

Country

• Belarus
• Bulgaria
• Croatia
• Denmark
• Indonesia
• Israel
• Italy
• Latvia
• Lithuania
• Malaysia
• Romania
• Singapore
• Thailand

Links

• nct
• ictrp